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Chapter 2
Trends in prescribing for heart
failure in Dutch primary care 
from 1996 to 2000
   Lisa G Pont, Miriam CJM Sturkenboom, Wiek H van Gilst,
Petra Denig and Flora M Haaijer-Ruskamp  
Provisionally accepted: The Annals of Pharmacotherapy 
Background: New evidence has emerged  during the past 15 years regarding
optimal pharmacotherapy for the treatment of chronic heart failure (CHF).
The aim of this study is to explore trends in primary care prescribing for CHF
over a 5-year period (1996-2000) focussing primarily on the incorporation of
new scientific evidence into daily practice.
Design: Repeated cross sectional surveys in a dynamic cohort. 
Setting: Integrated Primary Care Information (IPCI) primary care database.
Methods: Cohort members comprised all patients aged ≥ 55 years with a
diagnosis of CHF and treated with a cardiovascular medication during the
study period. The point prevalence per calendar year was determined for
each of the main drug groups used to treat CHF. Prescribing point
prevalences were also determined separately for new and chronic CHF
patients.  
Results: The study population consisted of 3121 CHF patients. Small
increases were seen in the percentage of CHF patients prescribed
spironolactone (4.6%, 95% CI: 2.3 to 6.9), β-blockers (6.1%, 95% CI: 2.6 to
9.5%) and angiotensin II antagonists (6.8%, 95% CI: 5.1 to 8.6%) during the
study period, while the prescribing of digoxin decreased (-4.4%, 95% CI: -8.2
to -0.7). Prescribing of diuretics (difference:-0.7% 95% CI: -2.7 to 4.2) and ACE
inhibitors (difference:4.0% 95% CI -0.1 to 8.2%) remained unchanged.
Discussion: Prescription of some drug groups for CHF increased, although
the changes observed were less than expected given the new scientific
evidence that has emerged in past years regarding optimal CHF
pharmacotherapy. Educational programs may help to minimise the gap
observed between the scientific evidence and prescribing for CHF in primary
care.
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Background
During the past 15 years, large international clinical trials have established
new scientific evidence in terms of improved prognosis and quality of life for
several drug groups that are commonly used for the treatment of chronic
heart failure CHF (Table 1). Angiotensin converting enzyme inhibitors
(ACEI), β-blockers and spironolactone have all been shown to improve the
symptoms and prognosis of CHF patients, while scientific evidence
regarding the use of digoxin for the treatment of CHF includes shows
improved quality of life and a reduction in hospital admissions1-6.





Diuretics no large RCT
ACEIs Consensus1 1987 31%↓ in mortality
SOLVD 12 1991 16%↓ in mortality
26%↓ in hospital admissions
β-blockers CIBIS-I3 1994 34%↓ in hospital admissions
MERIT-HF4 1999 34%↓ in mortality
Digoxin DIG study6 1997 28%↓ in hospital admissions
No effect on mortality
Spironolactone RALES5 1999 27%↓ in mortality
35%↓ in hospital admissions
Angiotensin II
antagonists
ELITE 27 2000 No difference in mortality
between losartan and
captopril
During the same period, it has become apparent that despite the advances
reported in the scientific literature, prescribing for CHF in daily practice is
sub-optimal8-10. Studies on the use of ACEI for CHF in both primary and
secondary care have shown delays in the uptake of clinical trials information
into clinical practice11 and such delays are also likely to exist for other drug
groups. While a lag time is known to exist between the publication of new
trials and the adoption of new therapies into clinical practice, the length of
this lag-time is unknown12. It has been suggested that specialists incorporate
new evidence in their daily practice faster than primary care physicians13.
However, since the majority of CHF patients are treated in primary care the
uptake of new evidence by primary care physicians is an important issue.
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Given the major advances regarding optimal heart failure management that
have occurred during the past 15 years, it could be expected that
corresponding changes would be seen in primary care in the way drugs are
prescribed for CHF. The aim of this study is to explore changes in prescribing
for CHF over a 5-year period (1996–2000) focusing primarily on the
incorporation of new scientific evidence from clinical trials into daily
practice.
Methods
Setting and study population
In this study we used computerised medical records from the Integrated
Primary Care Information (IPCI) database. This is a longitudinal
observational primary care database containing electronic medical records
for patients registered with participating Dutch primary care physicians
(PCPs)14. The IPCI database was established in 1992. The number of practices
contributing to the database increased from 50 in 1996 to 106 in 2000 and the
number of patients from 163,673 to 322,952 during this period. 
In the Netherlands, patients register with a single primary care physician
who has a gatekeeper role coordinating their medical care. PCPs contributing
to the IPCI database are not permitted to use paper records in addition to
their electronic medical records. Thus, the records held by each PCP can be
considered complete for each patient. A maximum of 3 months medication
can be prescribed on a single prescription. Patients referred to a specialist
may initially receive drug treatment from the specialist and then generally
return to their GP for further medication supply. 
Data source
Data in the IPCI database is coded and anonymous and the system complies
with the EC guidelines on the use of confidential data for medical research14.
Records for each patient include age and sex, symptoms, diagnoses,
laboratory tests and results, information on specialist referrals and hospital
admissions, PCP notes and prescription details. The prescription data
includes drug name, strength, dosage form, dose, quantity prescribed and
indication. Diagnoses and symptoms are entered either as free text or are
coded according to the International Classification for Primary Care (ICPC)15.
Medications are coded according to the Anatomical Therapeutic Chemical
(ATC) classification16.
Cohort definition 
Patients with a diagnosis of CHF who were prescribed a cardiovascular
medication (ATC code: C*) during the study period were identified from the
medical files using either the ICPC coded diagnoses or free text. All potential
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heart failure patients younger than 55 were excluded. Patients with a CHF
diagnosis who were not prescribed a cardiovascular medication were also
excluded since an untreated CHF diagnosis may indicate diagnostic
uncertainty on behalf of the prescriber. We recruited CHF patients treated
with any cardiovascular medication to ensure that patients treated with
drugs other than those in which we were interested were also included.
Patients entered follow-up when all of the following conditions were
fulfilled: diagnosis of CHF, 6 months of valid history (registered for 6 months
and PCP participating in IPCI for at least 6 months). Follow-up ended on the
earliest of the following dates: end of the study period, death, transfer to a
non-participating PCP, or last data drawn.
Outcome measurement
To explore trends in the pharmacological management of CHF in primary
care we calculated the point prevalence for specific drugs in the dynamic
cohort in the years 1996 until 2000. For each year, the first Wednesday in
October was used as the prevalence index date. On each prevalence index
date the cohort of CHF patients still actively followed at that date was
divided in new and chronic patients. A CHF patient was considered a new
patient if their first CHF diagnosis was in the 6 months preceding the index
date and a chronic patient if the initial CHF diagnosis was made more than 6
months before the index date.
Exposure definition
The main drug groups investigated in this study were those recommended in
the 1997 European Society of Cardiology guideline for the treatment of Heart
Failure17 which the European guideline current at the time of the study. The
drug groups included were diuretics, ACEI, β-blockers, digoxin, angiotensin
II antagonists and spironolactone. The diuretic groups available in the
Netherlands at the time of the study were chlorthalidone, chlorothiazide,
hydrochlorothiazide, indapamide, mefruside, bumetanide, furosemide,
ethacrynic acid, amiloride, triamterene, triamterene/epitizide,
triamterene/hydrochlorothiazide and potassium canrenoate. Patients were
considered current users of a drug on the prevalence index date if they had
received a prescription for one of the selected drug groups in a 6-month time
window prior to the index date. A 6-month time window was chosen since
the maximum period that may be supplied by one prescription in the
Netherlands is 3 months. Thus, within a 6-month period it can be expected
that a patient currently using a medication would be issued with at least one
prescription for that drug. 
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Analysis
Point prevalences of specific drug use were calculated each year by dividing
the number of CHF patients currently treated with the specified
cardiovascular medication by the total number of CHF patients who were
registered on the prevalence index date for the year. Point prevalences were
calculated overall and then stratified for chronic and new patients. Changes
in the prevalence estimates (2000-1996) were calculated for each drug group
during the 5-year period and 95% confidence intervals (95% CI) given around
all prevalence difference estimates.
Results
From the source population of approximately 63000 persons aged 55 years or
over in the IPCI database, we identified 3121 patients with a CHF diagnosis
of heart failure who were treated with a cardiovascular medication during
the period 1996 and 2000. Overall, the mean age of the CHF patients
increased 1.2 years (95% CI: 0.4 to 2.0) during the study period, from 77.3
years in 1996 to 78.4 years in 2000. When separated into new and chronic
patients, no increase in age was seen for the new patients. For this group the
mean age was 76.7 years (95% CI: 75.6 to 78.0) in 1996 and 77.4 years (95% CI:
76.2 to 78.7) in 2000. For the chronic patients, the mean age increased from
77.5 years (95% CI: 76.7 to 78.2) in 1996 to 78.6 years (95% CI: 78.1 to 79.0) in
2000. The proportion of male patients treated for heart failure increased
slightly throughout the 5 year period from 41.3% (95% CI: 37.9 to 44.6) in
1996, to 44.3% (95% CI: 41.9 to 46.7) in 2000. Similar increases were observed
for both new patients and chronic patients.
 
Figure 1 shows the prescribing trends observed for the selected heart failure
drug groups during the study period. Trends for all CHF patients are seen in
Figure 1a, new CHF patients in Figure 1b and chronic CHF patients in Figure
1c. The trends observed for all patients and for chronic patients were
comparable.
No significant change was seen in the prevalence of patients prescribed a
diuretic or an ACEI during 1996 to 2000 (Table 2). There was a significant
increase in prescription of spironolactone, β-blockers and angiotensin II
antagonists for chronic CHF patients. However, for the new patients only the
percentage of patients prescribed spironolactone increased significantly. The
percentage new and chronic heart failure patients prescribed digoxin
decreased during the 5-year study period.
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Conclusions
In this study, we examined prescribing trends for the treatment of CHF in
Dutch primary care over a 5-year period, from 1996 to 2000. Internationally,
considerable change has taken place over the past 15 years based on the
outcome from various clinical trials regarding what is considered optimal
CHF pharmacotherapy. We expected that these changes reported in the
scientific evidence would be reflected in changes in prescribing. However,
while the use of many drug groups for the treatment of heart failure
increased from 1996 to 2000, the changes observed in drug use did not appear
to follow the changes regarding optimal treatment published in the scientific
literature. 
Evidence regarding the benefits of ACEIs in the treatment of CHF was first
established in 1987 with the publication of the Consensus trial1. With further
studies strengthening their position in heart failure, the ACEIs are currently
considered first-line therapy for all heart failure patients2. Despite this wealth
of evidence, the percentage of patients treated with an ACEI in our study
population was low. The total number of heart failure patients treated with
an ACEI did increase by 4% during the study period, however, this increase
was not statistically significant. Given the strength of the evidence
supporting the use of ACEIs in the treatment of heart failure a greater
increase in the use of ACEIs for CHF was expected.
While little change was seen in the prescribing of the ACEIs, a considerable
increase was observed with respect to the angiotensin II antagonists. Use of
this drug group increased from 2.2% of all CHF patients in 1996 to 9.0% in
2000. Angiotensin II antagonists were first introduced onto the Dutch market
in 1995 and by 2000, six were available in the Netherlands. Clinical trials
have shown that these agents are equivalent not superior to the ACEIs for the
treatment of heart failure and they are generally recommended only as
alternatives to ACEIs for patients unable to tolerate ACEIs7. The increase seen
in this population is consistent with the introduction of a new drug group
onto the market18,19. While prescribing of angiotensin II antagonists increased
for both new and chronic CHF patients, a larger increase was seen for chronic
CHF patients. This supports the idea that these drugs are being used for
patients unable to tolerate ACEIs and not as first-line treatment for all CHF
patients.
Publication of the CIBIS study in 1994 revolutionised the use of β-blockers for
the treatment of CHF, reporting a 34% decrease in mortality with the use of
bisoprolol3. This finding was reinforced with the publication of the MERIT-
HF study4. Guidelines from the European Society of Cardiology published in
1997 recommend the use of β-blockers in CHF but only under specialist care.
Trends in prescribing for heart failure     21
The current European guidelines (2001) recommend the use of β-blockers in
patients with moderate heart failure20. While the prescription of β-blockers
for heart failure patients has steadily increased since 1996, use of β-blockers
for CHF in primary care is still low. Since many CHF patients have coexisting
cardiovascular conditions such as hypertension or myocardial infarction for
which β-blockers are also indicated21,22 it is possible that β-blockers prescribed
to the CHF patients in this study were actually for the treatment of comorbid
conditions rather than for CHF. One factor contributing to the slow adoption
of the new clinical trial evidence for β-blockers is that β-blockers have
traditionally been contraindicated for use in heart failure patients. The Dutch
primary care heart failure guideline, published in 1995, recommended that
these agents should not be used in heart failure patients, even for the
treatment of comorbid conditions23. That no significant increase was seen in
the prescription of β-blockers to new CHF patients may further be explained
by differences in CHF severity between new and chronic patients. Many new
patients may present with less severe heart failure and may be adequately
treated with ACEI monotherapy.
The only drug group to show a decrease in use during the 5-year study
period was digoxin. Evidence from the DIG study published in 1997, showed
that while digoxin had no effect on CHF mortality it did reduce hospital
admissions and improve quality of life6. Nevertheless, the use of digoxin
decreased from 29.4% of all heart failure patients in 1996 to 25.5% in 2000.
Similar decreases were seen with respect to the prescribing of digoxin for
both new and chronic CHF patients. The Dutch primary care guideline for
the treatment of heart failure recommends digoxin as first-line therapy for
CHF patients with co-existing atrial fibrillation23. However, prior to the
introduction of the ACEIs, first-line treatment for CHF in primary care
generally consisted of a combination of diuretics and digoxin. The decrease
in the use of digoxin for CHF patients that was observed in this study most
likely reflects these changes in the role of digoxin with respect to treatment of
CHF in primary care.
Prescribing of spironolactone increased significantly for both new and
chronic CHF patients. Publication of the RALES study in 1999 demonstrated
the benefits of spironolactone as an adjuvant therapy along with ACEI and
diuretics for patients with moderate to severe heart failure5. Overall,
prescribing of spironolactone appeared to decline from 1996 to 1998 and then
increased again from 1999. While this increase occurs around the time of the
publication of the RALES trial, in this study we are unable to establish a
causal effect. Interestingly, similar increases in the use of spironolactone were
observed for both new and chronic CHF patients.
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Traditionally, diuretics have been seen as first-line therapy for the treatment
of CHF and while there are no major clinical trials involving these agents,
their role in the alleviating the symptoms of heart failure is well established.
As could be expected, no significant change was seen the prescription of
diuretics. Prescribing of diuretics was slightly higher for new CHF patients
than for chronic patients but this most likely relates to an increased need for
reducing volume overload among newly diagnosed patients. 
In this study we have focused on the treatment of CHF in Dutch primary care
since in the Netherlands the PCP has a central role in the coordination of
patient care. Previous studies have shown that heart failure patients in the
Netherlands are less often treated with digoxin but more often with ACE
inhibitors or β-blockers than in other countries in Western Europe24.
However, drug use observed in this study is comparable with that reported
in other European primary care CHF populations25,26. 
A repeated cross-sectional survey design based on a dynamic cohort was
chosen to examine changes in the drug-use point prevalences during a 5-year
period. An important consideration for the choice of this design is the high
mortality associated with CHF. Average survival time for a CHF patient is
less than 5 years, rendering a traditional cohort design unsuitable for
providing an overview of changes in the treatment over a 5-year period.
Furthermore, we were interested prescribing trends for both chronic and
newly diagnosed CHF patients. We defined a current drug user as a heart
failure patient who received a prescription for a particular drug in the
6-month time window prior to the index date each year. The difference
between definitions of a current user based on treatment duration and
methods based on any prescription during a 12-month time window prior to
the index date differ by less than 5%27. It is expected that the 6-month time
window used in this study would further lower this difference.
A limitation of this study is the lack of a specific diagnosis for each
medication. As with many cardiovascular drugs, the agents followed in this
work are all indicated in the treatment of multiple conditions and CHF
patients generally have a high prevalence of comorbid cardiovascular
diseases24. From the PCP records it could not always be ascertained for which
cardiovascular diagnosis a particular drug is being used and one drug may
be prescribed to simultaneously treat more than one cardiovascular diagnosis
in an individual patient. Increases seen in the use of some drugs may be
attributable to increased use for cardiovascular comorbidities, rather than to
increased use for the treatment of heart failure. However, each of the patients
included in this study had a diagnosis of CHF registered in their general
practice medical records. Given this, we can assume that the cardiovascular
medications included in this study were either prescribed directly for heart
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failure or in order to treat related cardiovascular comorbidities in heart
failure patients. 
While an increase was seen in the prescription of many of the drugs
commonly used to treat CHF, the increases were much smaller than could be
expected given the substantial changes in the evidence regarding optimal
CHF treatment. Differences between the patients recruited for clinical trials
and those treated in primary care may be one factor contributing towards
this28. Heart failure patients seen in primary care are older and have more
related comorbidities than those participating in clinical trials, which may
influence treatment decisions29. PCP fears of renal impairment and
hypotension have been well documented as barriers to optimal ACEI use30-33
and similar concerns regarding side effects may well play a role in under-
utilisation of other drug groups. This study focused treatment for CHF in
primary care. Data from a PCP database was used to determine current drug
use and medication prescribed by a specialist would not be routinely
captured in the PCP database and thus, would not have been assessed in this
study. Given that in the Netherlands patients referred to a specialist
generally return within 3-months to their PCP for further medication supply,
it is unlikely that specialist prescription would be for longer than a 3-month
period.
This study highlights the difficulties associated with translating the scientific
evidence from large randomised clinical trials into daily practice. An increase
was seen in the prescribing of most of the drug groups used to treat CHF
during the 5-year study period. However, given the advances in the scientific
literature regarding the use of these agents in the treatment of CHF, the
increases in prescribing observed were lower than expected. Further studies
are needed exploring the barriers to optimal heart failure care and
interventions bridging the gap between the current evidence and daily
practice appear pivotal if the management of heart failure in primary care is
to improve.
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